Michelle A. Petri, MD, MPH, prepared useful Practice Aids pertaining to systemic lupus erythematosus for this CME activity titled "Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2IDqqpz. CME credit will be available until June 11, 2019.
The potential effects of Caper (Capparis spinosa L.) in the treatment of diab...LucyPi1
Abstract Diabetic neuropathy (DN) is the most common form of neuropathy worldwide, with its prevalence rising alongside diabetes, and being characterized by sensory, motor or autonomic symptoms. DN is considered to be an incurable complication of diabetes, the management of which mainly consists of improving glycemic control, managing pain relief and ensuring continuous foot care. Although gabapentin, duloxetine and tricyclic antidepressants are commonly used to reduce patient symptoms, they do not affect the pathophysiology and progression of neuropathy. Furthermore, these drugs can have various side effects including insomnia, decreased appetite, arrhythmia, heart failure, and suicidal behavior. According to traditional Persian medicine, DN is recognized as a type of “Khadar” or “Esterkha” (a sensory or motor disorder, respectively) that occurs due to the accumulation of sugars in the peripheral nerves. Capparis spinosa L., commonly known as the caper plant, has been recommended in authentic sources of traditional Persian medicine to treat such disorders. In this study, we reviewed the pharmacological properties of C. spinosa using the Web of Science, PubMed, Scopus and Google Scholar databases, and found that Capparis spinosa L. could affect several pathways involved in DN pathogenesis, including aldose reductase activity, the secretion of inflammatory mediators (IL-17, TNF-α, IL-1β, IL-6), oxidative stress, hyperlipidemia, hyperglycemia and advanced glycation end product formation. Based on these findings, we hypothesize that Capparis spinosa L., may prevent the progression and reduce the symptoms of diabetic neuropathy, and so can be considered as a complementary treatment in this disorder. This hypothesis should be evaluated in well-designed in vitro and in vivo studies, and through clinical trials.
LGS Foundation 2016 Conference - Friday MorningLGS Foundation
Topics Include: Therapies for LGS (Part One) - Pharmacological, presented by Angus A WIlfong, MD and Therapies for LGS (Part 2) - Non-Pharmacological presented by Scott Demarest, MD
The potential effects of Caper (Capparis spinosa L.) in the treatment of diab...LucyPi1
Abstract Diabetic neuropathy (DN) is the most common form of neuropathy worldwide, with its prevalence rising alongside diabetes, and being characterized by sensory, motor or autonomic symptoms. DN is considered to be an incurable complication of diabetes, the management of which mainly consists of improving glycemic control, managing pain relief and ensuring continuous foot care. Although gabapentin, duloxetine and tricyclic antidepressants are commonly used to reduce patient symptoms, they do not affect the pathophysiology and progression of neuropathy. Furthermore, these drugs can have various side effects including insomnia, decreased appetite, arrhythmia, heart failure, and suicidal behavior. According to traditional Persian medicine, DN is recognized as a type of “Khadar” or “Esterkha” (a sensory or motor disorder, respectively) that occurs due to the accumulation of sugars in the peripheral nerves. Capparis spinosa L., commonly known as the caper plant, has been recommended in authentic sources of traditional Persian medicine to treat such disorders. In this study, we reviewed the pharmacological properties of C. spinosa using the Web of Science, PubMed, Scopus and Google Scholar databases, and found that Capparis spinosa L. could affect several pathways involved in DN pathogenesis, including aldose reductase activity, the secretion of inflammatory mediators (IL-17, TNF-α, IL-1β, IL-6), oxidative stress, hyperlipidemia, hyperglycemia and advanced glycation end product formation. Based on these findings, we hypothesize that Capparis spinosa L., may prevent the progression and reduce the symptoms of diabetic neuropathy, and so can be considered as a complementary treatment in this disorder. This hypothesis should be evaluated in well-designed in vitro and in vivo studies, and through clinical trials.
LGS Foundation 2016 Conference - Friday MorningLGS Foundation
Topics Include: Therapies for LGS (Part One) - Pharmacological, presented by Angus A WIlfong, MD and Therapies for LGS (Part 2) - Non-Pharmacological presented by Scott Demarest, MD
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopitalUsama Ragab
Inpatient Diabetes Management
By Dr. Usama Ragab Youssif
Lecturer of Medicine Zagazig University
Why we need this lecture?
Diabetes inhospital is common problem
Increased diabetes morbidities
Increased mortality
Kenneth C. Kalunian, MD, Maureen A. McMahon, MD, and Joan T. Merrill, MD, prepared useful practice aids pertaining to systemic lupus erythematosus for this CME activity titled "Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment to Provide Optimal Care for Each Patient." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at https://bit.ly/2zki5EQ. CME credit will be available until September 14, 2021.
Lupus is a chronic autoimmune disease that occurs when a person's immune system attacks their own tissues and organs. Learn about the symptoms of lupus, how it is diagnosed and new treatment options to live well with lupus.
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopitalUsama Ragab
Inpatient Diabetes Management
By Dr. Usama Ragab Youssif
Lecturer of Medicine Zagazig University
Why we need this lecture?
Diabetes inhospital is common problem
Increased diabetes morbidities
Increased mortality
Kenneth C. Kalunian, MD, Maureen A. McMahon, MD, and Joan T. Merrill, MD, prepared useful practice aids pertaining to systemic lupus erythematosus for this CME activity titled "Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment to Provide Optimal Care for Each Patient." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at https://bit.ly/2zki5EQ. CME credit will be available until September 14, 2021.
Lupus is a chronic autoimmune disease that occurs when a person's immune system attacks their own tissues and organs. Learn about the symptoms of lupus, how it is diagnosed and new treatment options to live well with lupus.
Chair, Monica Gandhi, MD, MPH, prepared useful Practice Aids pertaining to HIV for this CME/MOC/CE/AAPA activity titled “Adapting HIV Treatment for People With Substance Use Disorder.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CE/AAPA information, and to apply for credit, please visit us at https://bit.ly/49hgPxT. CME/MOC/CE/AAPA credit will be available until June 4, 2025.
Chair, Monica Gandhi, MD, MPH, discusses HIV in this CME/MOC/CE/AAPA activity titled “Adapting HIV Treatment for People With Substance Use Disorder.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CE/AAPA information, and to apply for credit, please visit us at https://bit.ly/49hgPxT. CME/MOC/CE/AAPA credit will be available until June 4, 2025.
Chair, Carla M. Nester, MD, MSA, FASN, discusses glomerular kidney disease in this CME activity titled “Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evolving Landscape of Glomerular Kidney Disease Management.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3wJPTs1. CME credit will be available until June 4, 2025.
Chair and Presenter Rohit Loomba, MD, MHSc, and Alina M. Allen, MD, MS, discuss metabolic dysfunction–associated steatohepatitis in this CME activity titled “Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3O53xMy. CME credit will be available until June 19, 2025.
Co-Chairs, Prof. Mohamad Mohty, MD, PhD, and Caitlin Costello, MD, discuss refractory multiple myeloma in this CME/CPD activity titled “Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM.” For the full presentation, downloadable Practice Aids, and complete CME/CPD information, and to apply for credit, please visit us at https://bit.ly/3UFL0dt. CME/CPD credit will be available until 5 June 2025.
Co-Chairs, Doreen J. Addrizzo-Harris, MD, and Cedric "Jamie" Rutland, MD, discuss non-cystic fibrosis bronchiectasis in this CME/MOC/AAPA activity titled “Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3KlxjL9. CME/MOC/AAPA credit will be available until June 19, 2025.
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, discuss non-cystic fibrosis bronchiectasis in this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Jonathan E. McConathy, MD, PhD, and Gil Rabinovici, MD, discuss Alzheimer's disease in this CME/AAPA activity titled “Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/45RFl6g. CME/AAPA credit will be available until June 15, 2025.
Co-Chairs Sarah Hayward, PharmD, BCOP, and Ambar Khan, PharmD, BCOP, discuss endometrial and cervical cancers in this CME/CPE/IPCE activity titled “A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care.” For the full presentation, downloadable Practice Aids, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3wGBPQp. CME/CPE/IPCE credit will be available until May 27, 2025.
Co-Chairs, Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD, discuss multiple myeloma in this CME activity titled “‘Four-Ward’ Progress in NDMM: New Developments With CD38 Antibody Quadruplets.” For the full presentation and complete CME information, and to apply for credit, please visit us at https://bit.ly/3x3oWA3. CME credit will be available until May 23, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, discuss lung cancer in this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Chair Oliver Sartor, MD, discusses prostate cancer in this CME activity titled “On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/49oY4IJ. CME credit will be available until May 23, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair, Nicholas J. Short, MD, discusses acute lymphoblastic leukemia in this CME/NCPD/CPE/AAPA/IPCE activity titled “Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies & MRD-Guided Strategies Across Disease Settings.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/42QsTDT. CME/NCPD/CPE/AAPA/IPCE credit will be available until May 22, 2025.
Chair, Sharon Cohen, MD, FRCPC, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair, Sharon Cohen, MD, FRCPC, discusses Alzheimer’s disease in this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
More from PVI, PeerView Institute for Medical Education (20)
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician
1. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Information for Patients:
Lupus Medications and
Treatment Options1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
DHEA: dehydroepiandrosterone; NSAID: nonsteroidal anti-inflammatory drugs.
1. https://www.hopkinslupus.org/lupus-treatment/. Accessed May 11, 2018.
NSAIDs
• These anti-inflammatory medications relieve some lupus symptoms by reducing the inflammation
responsible for the stiffness and discomfort in your muscles, joints, and other tissues
• NSAIDs are milder than many other lupus drugs and may be taken either alone to treat a mild flare
or in combination with other medications
Antimalarial drugs
• Plaquenil (hydroxychloroquine) and other antimalarials are the key to controlling lupus long term,
and some lupus patients may be on Plaquenil for the rest of their lives; for this reason, you can
think of antimalarials as a sort of “lupus life insurance”
Steroids
• Synthetic cortisone medications are some of the most effective treatments for reducing the
swelling, warmth, pain, and tenderness associated with the inflammation of lupus; cortisone
usually works quickly to relieve these symptoms
• However, cortisone can also cause many unwelcome side effects, so it is usually prescribed only
when other medications—specifically NSAIDs and anti-malarials—are not sufficient enough to
control lupus
Immunosuppressive medications
• Immunosuppressives are medications that help suppress the immune system; many were
originally used in patients who received organ transplants to help prevent their bodies from
rejecting the transplanted organ
• However, these drugs (eg, methotrexate, azathioprine, belimumab) are now also used for the
treatment of certain autoimmune diseases, such as lupus and rheumatoid arthritis
DHEA
• DHEA is a mild male hormone that is effective in treating some of the symptoms of mild to
moderate lupus, including hair loss (alopecia), joint pain, fatigue, and cognitive dysfunction
(eg, difficulty thinking, memory loss, distractibility, difficulty in multitasking); DHEA can also be
effective against osteoporosis
2. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Systemic Lupus International
Collaborating Clinics (SLICC)
Classification Criteria for Systemic
Lupus Erythematosus1
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
ANA: antinuclear antibody; C3: complement 3; C4: complement 4; CH50: total complement; dsDNA: double-stranded DNA; ELISA: enzyme-linked immunosorbent assay; IgA: immunoglobulin A;
IgG: immunoglobulin G; IgM: immunoglobulin M; RPR: rapid plasma regain; SLE: systemic lupus erythematosus; Sm: Smith antibody.
1. Petri M et al. Arthritis Rheum. 2012 ;64:2677-2686.
PRACTICE AID
Clinical Criteria
1. Acute/subacute cutaneous lupus
Lupus malar rash (do not count if malar discoid)
Bullous lupus
Toxic epidermal necrolysis variant of SLE
Maculopapular lupus rash
Photosensitive lupus rash (in the absence of dermatomyositis) OR subacute cutaneous lupus (nonindurated psoriaform and/or
annular polycyclic lesions that resolve without scarring, although occasionally with postinflammatory dyspigmentation or telangiectasias)
2. Chronic cutaneous lupus
Classic discoid rash (localized [above the neck] or generalized [above and below the neck]), hypertrophic (verrucous) lupus, lupus
panniculitis (profundus), mucosal lupus, lupus erythematosus tumidus, chilblains lupus, OR discoid lupus/lichen planus overlap
3. Oral ulcers (palate [buccal or tongue]) OR nasal ulcers (in the absence of other causes, such as vasculitis, Behçet's disease, infection
[herpesvirus], inflammatory bowel disease, reactive arthritis, and acidic foods)
4. Nonscarring alopecia
Diffuse thinning or hair fragility with visible broken hairs (in the absence of other causes, such as alopecia areata, drugs, iron deficiency, and
androgenic alopecia)
5. Synovitis involving 2 or more joints, characterized by swelling or effusion OR tenderness in 2 or more joints and
30 minutes or more of morning stiffness
6. Serositis
Typical pleurisy for more than 1 day, pleural effusions, or pleural rub, OR typical pericardial pain (pain with recumbency improved by sitting
forward) for more than 1 day, pericardial effusion, pericardial rub, OR pericarditis by electrocardiography (in the absence of other causes,
such as infection, uremia, and Dressler's syndrome)
7. Renal
Urine protein/creatinine (or 24-hour urine protein) representing at least 500 mg of protein/24 hours OR red blood cell casts
8. Neurologic: seizures, psychosis, mononeuritis multiplex, myelitis, peripheral or cranial neuropathy, cerebritis
(acute confusional state)
9. Hemolytic anemia
10. Leukopenia (<4,000/mm3
at least once) OR lymphopenia (<1,000/mm3
at least once)
11. Thrombocytopenia (<100,000/mm3
) at least once
Immunologic Criteria
1. ANA above laboratory reference range
2. Anti-dsDNA above laboratory reference range, except ELISA (twice above laboratory reference range)
3. Anti-Sm
4. Antiphospholipid antibody, determined by any of the following
Lupus anticoagulant
False-positive RPR
Medium- or high-titer anticardiolipin (IgA, IgG, or IgM)
Anti-β2-glycoprotein 1 (IgA, IgG, or IgM)
5. Low complement
Low C3
Low C4
Low CH50
6. Direct Coombs test (in the absence of hemolytic anemia)
Classify a patient as having SLE if
• The patient satisfies four of the criteria listed in the table above, including at least one clinical criterion and one
immunologic criterion
OR
• The patient has biopsy-proven nephritis compatible with SLE and with ANA or anti-dsDNA antibodies
3. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Information for Patients:
Common Medications for Other
Conditions in People With Lupus1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Aspirin
• Low doses of aspirin are often recommended for lupus patients who have antiphospholipid antibodies
and may reduce the risk of heart attack and stroke
Antidepressants
• Antidepressant medications are used to treat depression and anxiety, which is present in almost half of all
people who have lupus
• It is important that you speak with your doctor if you feel you are experiencing clinical depression,
because many people who are physically ill respond well to antidepressant medications; in addition,
your doctor may treat your depression in different ways depending on the cause
Antiplatelet medications (platelet antagonists)
• Some lupus patients are at an increased risk for blood clots because of the prevalence of a condition
known as antiphospholipid antibody syndrome (APS); platelet antagonists help prevent these clots and,
in doing so, also help to prevent heart attack, stroke, and other complications
Osteoporosis medications (bisphosphonates)
• Bisphosponates are medications used to treat and prevent osteoporosis; people with lupus are at an
increased risk for this condition because of the inflammation they experience with the disease
• Certain medications taken by lupus patients also increase the risk of osteoporosis, especially
corticosteroids such as prednisone
Blood pressure medications (antihypertensives)
• 25% to 30% of people with lupus experience hypertension (high blood pressure); the most common
causes of high blood pressure in people with lupus are kidney disease and long-term steroid use
• Other medications, such as cyclosporine (Neoral, Sandimmune, Gengraf) can also cause elevations in
blood pressure
• It is important to remember that while diet and exercise are extremely important for optimal cardiovascular
health, these elements alone may be insufficient in controlling your blood pressure; in this case, your doctor
will prescribe a medication
Anticoagulants
• Anticoagulants (“blood thinners”) are medications that decrease the ability of the blood to clot and are
used in lupus patients with antiphospholipid antibodies to reduce the risk of deep venous thrombosis
(DVT), stroke, and heart attack
Gastrointestinal medications
• Many people with lupus suffer from gastrointestinal problems, especially heartburn caused by
gastroesophageal reflux disease (GERD); peptic ulcers can also occur, often because of certain medications
used in lupus treatment, including NSAIDs and steroids
• Certain medications may be prescribed or recommended by your doctor to control these conditions
4. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Information for Patients:
Common Medications for Other
Conditions in People With Lupus1
PRACTICE AID
1. https://www.hopkinslupus.org/lupus-treatment/. Accessed May 11, 2018.
Cholesterol medications (statins)
• Statins are medications that lower the level of cholesterol in your blood by reducing the production
of cholesterol in the liver; people with high levels of cholesterol in their blood face an increased risk of
cardiovascular disease, which can lead to chest pain, heart attack, stroke, and peripheral vascular disease
• Studies have shown that people with lupus are more likely to have clogged arteries that can lead to heart
attack and stroke at a younger age; this increased risk is caused by elevated cholesterol levels, high blood
pressure, diabetes, and inflammation, conditions that occur often in people with lupus
• Certain medications, such as corticosteroids (eg, prednisone), can provoke or compound these symptoms;
for this reason, the cholesterol-lowering properties of statins are commonly called upon for lupus patients
Thyroid medications
• Autoimmune thyroid disease is common in lupus; it is believed that about 6% of people with lupus have
hypothyroidism (underactive thyroid) and about 2% have hyperthyroidism (overactive thyroid)
• A thyroid gland that is functioning improperly can affect the function of organs such as the brain, heart,
kidneys, liver, and skin
• Hypothyroidism can cause weight gain, fatigue, depression, moodiness, and dry hair and skin;
hyperthyroidism can cause weight loss, heart palpitations, tremors, and heat intolerance, and can
eventually lead to osteoporosis
• Treatment for both underactive and overactive thyroid involves getting your body’s metabolism back
to normal
Fibromyalgia medications
• Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness, general fatigue,
and nonrestful sleep
• Many people with lupus have fibromyalgia; in fact, much of the pain that people with lupus feel is because
of this condition
• Three medications are used to reduce some of the physical and emotional symptoms of fibromyalgia
Restasis (dry eye medication)
• Restasis is an immunosuppressive medication used to treat eye symptoms related to Sjogren’s syndrome,
a chronic autoimmune disorder in which the glands that produce tears and saliva do not function correctly
5. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Information for Patients:
Lifestyle Information1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
1. https://www.hopkinslupus.org/lupus-info/lifestyle-additional-information/. Accessed May 11, 2018.
THINGS TO
AVOID
Sunlight
Echinacea
Bactrim and Septra
(sulfamethoxazole and
trimethoprim)
Alfalfa sprouts
Melatonin and
Rozerem (ramelteon)
Garlic